reduc risk relaps
nmosd initi ow
initi overweight pt inebilizumab de-
risk clinic think like approv
becom one favor treatment
nmosd albeit increasingli competit market
addit compani develop broad pipelin
viela focus autoimmun diseas develop therapi
autoimmun inflammatori diseas focus key pathway
share multipl indic compani report posit phase data
inebilizumab earlier year neuromyel optica spectrum disord nmosd
rare autoimmun disord lead blind paralysi model
viela target nmosd patient peak market share
think may prove conserv addit compani initi
studi three addit indic inebilizumab next month
two indic year-end
inebilizumab could second approv treatment nmosd mid-
base posit phase data think inebilizumab like
becom second approv treatment nmosd physician spoken
view efficaci inebilizumab compar treatment
nmosd alexion soliri approv june roche/chugai
satralizumab addit expert indic would like prescrib
inebilizumab satralizumab often particularli front-lin patient
given high price soliri data support use soliri sever
patient howev investor express skeptic viela abil new sale
forc compet larger establish sale forc alexion
roch alexion cover matthew harrison roch cover mark
purcel chugai cover shinichiro muraoka
pipelin offer upsid potenti viela also develop inebilizumab three
addit indic greater confid myasthenia gravi
addit viela begin phase studi year kidney
transplant reject sjgren syndrom overal unadjust peak us
sale target patient pipelin program
target nmosd patient heavili risk-adjust pipelin
program remain rel earli
valuat overweight pt model peak unadjust us sale
inebilizumab nmosd
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
inebilizumab nmosd drive risk/reward
inebilizumab nmosd drive risk/reward
pt deriv discount cash flow analysi assum
discount rate termin growth valu assum peak us
market share nmosd adjust use probabl
inebilizumab approv nmosd faster uptak assum
po higher peak share quicker ramp launch also assum higher
po pipelin program mg sjgren kidney transplant
base case assumpt describ price target methodolog
fda request addit data result delay approv assum
lower po inebilizumab nmo assum slower uptak
overweight viela compani
develop treatment autoimmun
inebilizumab clinic de-risk
nmosd follow posit phase data
think like approv mid-
believ inebilizumab like one
favor treatment front-lin
addit
indic inebilizumab provid
opportun upsid
upcom catalyst
begin phase studi inebilizumab
begin phase studi kidney
submit ind begin phase studi
sjgren
potenti approv inebilizumab
risk achiev price
fda may approv inebilizumab
launch inebilizumab nmosd may
slower expect due intens
competit soliri satralizumab
lack advanc pipelin
initi coverag viela overweight rate price target
clinic stage compani develop treatment autoimmun sever
inflammatori diseas compani start acquisit six molecul
medimmun viela lead candid inebilizumab target autoantibody-gener
cell viela present posit phase data n-momentum studi earlier
year indic inebilizumab reduc risk attack patient
neuromyel optica spectrum disord nmosd autoimmun diseas lead
blind paralysi compani submit biolog licens applic bla
june could receiv approv viela develop inebilizumab three
indic well addit indic
think highli like inebilizumab approv acknowledg
viela like face near-term competit headwind alexion soliri approv
june roch satralizumab potenti approv off-label rituxan
howev find reassur compani move ahead quickli advanc
addit program pipelin think could provid substanti upsid
come year
debat discuss report
debat inebilizumab differenti clinic soliri satralizumab
debat viela abl compet alexion roch off-label rituxan
debat potenti upsid outsid nmosd
exhibit summari peak sale project
inebilizumab de-risk clinic viela phase n-momentum studi inebilizumab
reduc risk attack aquaporin posit autoantibodi
major nmosd patient test posit patient overal studi
popul reduc risk attack import nmosd attack reduc
function patient perman
inebilizumab like one favor treatment front-lin nmosd base
convers expert physician believ inebilizumab satralizumab
like favor newli diagnos nmosd patient physician spoke
believ efficaci data soliri inebilizumab satralizumab fairli
compar even though data numer higher patient soliri
expert believ use soliri seriou patient given expect
significantli higher cost soliri least expect inebilizumab
soliri phase focus relaps patient
compani develop broad pipelin viela develop inebilizumab
desensit diseas addit
phase phase trial respect treatment addit autoimmun
viela manag substanti expertis autoimmun diseas found
manag team signific portion research develop team
join medimmun astrazeneca biolog divis member
manag team work togeth public compani focus autoimmun
diseas other work togeth decad
exhibit upcom catalyst stock-impact event highlight
price target includ risk-adjust peak us sale deriv price
target discount cash flow dcf analysi use discount rate
discount rate use discount rate commerci compani
compani random phase data develop stage compani
although inebilizumab yet approv incorpor discount rate
believ like approv
termin growth rate model revenu assum termin
revenu model revenu inebilizumab nmosd mg
sjgren kidney transplant reject assumpt launch year peak
sale indic shown exhibit
econom viela maintain world-wide right inebilizumab besid hansoh
group develop market inebilizumab china hong kong
macau current base case assumpt viela commerci us
partner europ result assum royalti rate low high teen europ
risk price target risk includ clinic regulatori legal commerci
challeng specif viela fda may approv inebilizumab nmosd
inebilizumab may face strong competit soliri satralizumab off-label
rituxan addit concern pml could remain overhang final viela could
fail advanc pipelin candid like inebilizumab addit
debat inebilizumab differenti clinic soliri
overview inebilizumab viela lead candid treat neuromyel optica
spectrum disord nmosd inebilizumab deplet express cell
limit bodi autoimmun respons histor treatment nmosd includ
corticosteroid immunosuppress addit alexion soliri receiv
approv late june phase data read viela inebilizumab
street take investor argu soliri better efficaci greater
reduct risk attack meanwhil investor compar inebilizumab
data satralizumab argu differenti
take think inebilizumab like view similarli
nmosd drug efficaci howev expert see inebilizumab satralizumab
similar given posit monotherapi data less sever patient would
support use front-lin patient still viela may abl offer differenti
three secondari endpoint met phase
background nmosd
neuromyel optica spectrum disord nmosd rare autoimmun diseas
central nervou system character inflamm optic nerv optic neuriti
spinal cord myeliti exact caus nmosd unknown bodi
natur defens attack healthi tissu protein central nervou system
attack autoantibodi caus autoreact cell lead harm
inflamm approxim nmosd patient posit
patient like experi relaps relaps lead cumul
function declin exhibit symptom includ pain eye loss clear vision
loss motor sensori bladder/bowel function ultim attack
lead blind paralysi death earli stage nmosd often mistaken
multipl sclerosi ms due common optic neuriti myeliti may lead
delay diagnosi
approxim patient nmosd us eu
patient nmosd experi recurr attack separ period remiss
could last week month year acut attack patient normal
treat corticosteroid methylprednisolon may return
vision motor function patient often left perman damag goal
treatment maintain remiss extend time next attack achiev
drug like mycophenol mofetil azathioprin rituximab use
mainten therapi extend remiss although none approv
nmosd alexion soliri eculizumab approv june becam first
exhibit function declin nmosd patient often observ follow attack
viela lead program inebilizumab human monoclon antibodi target
express cell administ intraven inebilizumab bind
broadli express cell initi cell deplet antibodi depend
cellular cytotox adcc antibodi depend cellular phagocytosi adcp
suppress cell fewer autoantibodi produc reduc autoimmun
exhibit inebilizumab bind express cell stop product autoantibodi
june viela submit biolog licens applic bla accept
review fda pdufa date june data submit bla
n-momentum phase trial open label extens remain
on-going patient receiv inebilizumab everi six month
inebilizumab reduc risk attack patient
overal intent-to-treat patient popul reduc
risk attack critic nmosd damag recurr attack perman
lead long-term disabl statist signific benefit observ
secondari endpoint popul exhibit
exhibit inebilizumab reduc risk attack patient overal
exhibit kaplan-mei curv illustr probabl attack patient
exhibit inebilizumab met secondari endpoint phase studi
overal inebilizumab shown favor safeti profil phase studi similar
proport patient inebilizumab placebo experienc advers event
phase vs urinari tract infect arthralgia back pain headach fall
hypoesthesia cystiti eye pain slightli frequent observ patient
inebilizumab sever advers event sae observ less frequent
inebilizumab placebo vs
death report on-going open label period one consid
unrel inebilizumab caus myeliti attack follow pneumonia
second death due complic mechan ventilator-associ
pneumonia although exact caus definit determin patient
develop new neurolog symptom seizur first lab test show
individu test posit john cunningham viru jcv howev retest two
lab includ nation institut jcv- remind
signific jcv jcv patient develop progress multifoc
leukoencephalopathi pml seriou brain infect cure
deadli rare pml report antibodi like rituxan
ocrevu expert spoken gener concern almost
evid pml howev believ hard proven given low
risk expect pml becom issu inebilizumab think may
remain back investor mind
comparison nmosd data physician feedback
date phase data read alexion soliri viela inebilizumab roch
satralizumab exhibit one area pushback heard investor
differenti inebilizumab particularli sinc soliri shown greater reduct
risk acknowledg soliri show greater reduct risk attack
patient vs inebilizumab satralizumab
physician spoken view efficaci data fairli compar argu
slightli better efficaci soliri off-set black box warn
meningococc infect higher price lack monotherapi data remind
inebilizumab n-momentum data satralizumab sakurastar data monotherapi
soliri prevent data add-on therapi expert indic
would like prescrib inebilizumab satralizumab front-lin patient
exhibit comparison phase data soliri inebilizumab satralizumab
soliri approv soliri develop alexion approv june
first drug nmosd patient soliri initi approv
treatment paroxysm nocturn hemoglobinuria pnh phase prevent trial
soliri reduc risk attack patient efficaci appear
superior drug import distinct soliri trial
trial test sever patient histor annual relaps rate within
month prior screen kol spoke indic would expect see
greater improv risk attack sever patient popul trend
consist seen inebilizumab satralizumab studi upon
subgroup analysi drug test add-on therapi difficult
distil effect relat soliri
addit soliri sever drawback term safeti cost dose
conveni drug dose everi two week greater burden
drug soliri also sever safeti issu includ black box warn
meningococc infect kol spoke wari indic
would consid factor heavili prescrib given patient would need
monitor close infect could life threaten one kol indic
would consid prescrib patient get first infect anoth concern
doctor soliri expens physician expect payor play key role
drug prescrib due cost safeti concern kol
spoke expect use soliri second-lin treatment sever
inebilizumab pdufa june inebilizumab human monoclon
antibodi expect second nmosd drug market inebilizumab
reduc risk attack patient overal patient
popul inebilizumab administ monotherapi also achiev statist
signific secondari endpoint drug dose via iv day
everi month less frequent dose soliri satralizumab although
manag disclos price expect half soliri
satralizumab mse approv satralizumab antibodi
studi monotherapi combin immunosuppress phase
studi risk reduct patient reduct
overal popul reduct patient doctor encourag
data view larg in-lin inebilizumab dose week
everi week dose sub-cutan unlik infus
drug price still unknown satralizumab would expect less
soliri line inebilizumab
market opportun model assumpt
alexion estim target popul relaps nmosd patient
us soliri roch believ market opportun
satralizumab nmosd
assum patient us patient eu
model launch inebilizumab us launch
eu although patient includ phase studi conclus
could made given patient result
includ patient model model gross price per year
us peak market share probabl success impli peak us
sale think reason given current visiblealpha
consensu us soliri nmosd twice price current
unadjust peak ww sale assum viela partner inebilizumab
europ receiv low- high-teen royalti addit assumpt see market
debat viela abl compet alexion roch
off-label rituxan
overview alexion soliri approv nmosd june roch remain
track file satralizumab expect launch us
eu shortli furthermor alexion ultomiri could anoth
competitor within year conveni dose soliri
abp biosimilar soliri could also reach market next
year alexion track begin phase bridg subcutan dose
plan price discount soliri meanwhil rituxan
rituximab use off-label treat nmosd physician spoken
comfort use mani current prescrib
half nmosd patient launch viela plan target newli diagnos
patient rather tri convert patient alreadi rituxan addit plan
focu eight us center excel
street take competit frequent cite concern amongst investor
spoken specif investor express skeptic viela abil
new sale forc compet larger establish sale forc
alexion roch
take agre competit like fierc two brand drug
larger compani off-label rituxan potenti ultomiri next year
think viela strategi focus center excel help
compet alexion roch focus
person sale team expert spoken indic like
use inebilizumab satralizumab front-lin patient soliri use
subsequ sever patient base physician feedback
comparison respect phase data believ inebilizumab
satralizumab like closer competitor soliri far behind see
market share assumpt exhibit regard rituxan everi
physician talk said chang patient well-
maintain rituxan result think make sens viela focu
effort newli diagnos patient given total competit
pressur expect inebilizumab launch gradual
viela expect commerci immedi follow potenti approv
inebilizumab pdufa june plan commerci us partner ex-
us compani announc may collabor hansoh pharma develop
market inebilizumab china hong kong macau us viela expect hire
salesforc rep target center excel
highest prescrib physician physician exhibit approxim
patient nmosd us seen center viela believ focus
effort center compani abl target larg number
patient cost-effect manner especi consid go
compani like alexion roch significantli larger sale forc
viela plan focu initi newli diagnos patient major
treat nmosd specialist ms specialist commun neurologist viela cite
newli diagnos patient roughli line feedback
heard physician regard patient newli diagnos
midpoint viela rang us nmosd patient manag expect
launch slow steadi expect hockey stick
exhibit viela target center excel coe
inebilizumab like second drug market nmosd still face
great competit off-label rituxan rituximab rituxan monoclon antibodi
target express cell initi approv drug
approv non-hodgkin lymphoma chronic lymphocyt leukemia rheumatoid
arthriti although control studi conduct rituxan nmosd
literatur suggest rituxan decreas attack frequenc sever patient
nmosd etemadifar et al decreas expand
disabl statu scale edss patient studi reduc median
length spinal cord lesion therapi howev rituxan remov attack
entir even treatment modifi achiev consist cell deplet
although rituxan approv nmosd doctor familiar comfort
rituxan use substanti proport nmosd patient still
rituxan without safeti concern black box warn fatal infusion-
relat reaction sever mucocutan reaction hepat reactiv
importantli two biosimilar approv fda anoth
amgen/allergan yet file exhibit result believ inebilizumab
like face headwind brand biosimilar rituxan price
pressur well
exhibit rituxan biosimilar approv develop
viela believ inebilizumab differenti rituxan target
broadli express target inebilizumab would cover
cell drug well plasmablast plasma cell
contribut pathogen autoantibodi drive autoimmun diseas exhibit
kol spoke believ physician would like comfort
alreadi comfort cell deplet
exhibit express across cell
spoke neurologist ophthalmologist academ privat practic
sever theme emerg consist across expert
physician comfort rituxan gener expert estim
patient current rituxan physician consist said
rare ever issu get rituxan reimburs addit everi doctor
spoke indic would switch patient rituxan patient
well-maintain mani patient well-maintain rituxan
optim dose relaps meali et al jama neurol doctor
comfort drug kol expect adopt inebilizumab slow
potenti take year matur
physician sure would use inebilizumab rituxan given
similar effect cell deplet inde expert think
differenti mechan action would expect
clinic benefit result doctor might consid satralizumab
soliri anti-compl instead
expert divid differenti efficaci agre show good
efficaci mani doctor spoke view data larg in-lin
although note soliri slight edg doctor stress
decis would like come cost safeti conveni reimburs
patient choic consist heard soliri would like second-lin choic
given soliri expens black box warn
doctor mix rituxan go forward mani still plan offer choic
patient sever physician spoke estim rituxan still
share market matur expert thought dose frequenc
inebilizumab offer greater conveni rituxan vs year meanwhil
patient prefer subcutan administr satralizumab option
base kol feedback alexion prior expect linear trajectori
rather bolu uptak model slower launch trajectori inebilizumab
see inebilizumab face fierc competit satralizumab soliri addit
headwind rituxan model rituxan/biosimilar market share
slowli decreas physician move newli
diagnos patient approv treatment patient rituxan relaps
believ satralizumab view similar inebilizumab soliri
use sever patient particularli given higher cost result model
peak market share inebilizumab satralizumab
model treatment mycophenol azathioprin initi
repres market decreas physician increas
usag approv drug nmosd rest assumpt see model
exhibit market share assumpt nmosd
debat potenti upsid outsid nmosd
overview beyond nmosd viela develop inebilizumab myasthenia gravi
mg diseas kidney transplant desensit pivot trial
mg expect begin phase kidney transplant
desensit begin year phase diseas
expect begin next year addit viela develop anti-
fusion protein sjgren syndrom kidney transplant reject
phase studi expect begin year final
phase cutan lupu erythematosu cle interim data expect
street take investor spoken ascrib valu
pipelin program given program enter
take think potenti upsid pipelin
acknowledg program still rel earli model
includ inebilizumab mg sjgren syndrom
kidney transplant reject risk-adjust program use
probabl success po respect believ conserv
given typic po assign program phase
indic like sjgren think conserv po warrant given
multipl recent failur orencia filgotinib indic
multipl mid-stag candid still develop compani
inebilizumab indic
myasthenia gravi mg pivot studi begin mg rare neuromuscular
autoimmun diseas character pathogen antibodi target acetylcholin
receptor muscle-specif receptor tyrosin kinas caus skelet muscl weak
mg affect peopl us treatment includ cholinesteras inhibitor
soliri thymectomi see mg higher likelihood succeed sinc
soliri show benefit mg nmo diseas similar
autoantibodi secret plasmablast play key role pathogenesi
howev soliri inebilizumab differ mechan remain cautious
optimist inebilizumab mg viela plan submit ind begin pivot trial
patient launch refractori model annual gross price
peak market share risk-adjust use probabl
success po translat peak risk-adjust us sale
viela expect begin phase studi kidney transplant desensit
patient us wait kidney transplant highli
sensit high level alloantibodi calcul panel-react antibodi
score patient wors clinic outcom post transplant
lower chanc get match organ viela plan begin
proof-of-concept phase inebilizumab /- year program remain
upsid model
phase expect begin diseas mark tumor-
like swell fibrosi organ may link plasmablast plasma
cell secret antibodi patient diseas elev level
correl diseas activ patient blood level
upper limit normal minor normal serum concentr
patient go month year without symptom diagnosi made almost
patient respond standard treatment steroid achiev
complet remiss relaps within year viela plan submit ind
begin phase studi time depend fda agenc
yet acknowledg diseas indic ultim compani
plan ask fda singl pivot trial would suffici indic
program remain upsid model
transmembran protein part tumor necrosi factor receptor
tnfr superfamili express varieti cell includ cell monocyt
dendrit cell bind partner commonli express
cell interact promot cell activ prolifer
interact import germin center respons isotyp class switch
respons t-depend antigen signal contribut pathogen
autoimmun respons disregul express observ
system lupu erythematosu sle rheumatoid arthriti ra psoriat arthriti
overexpress correl higher diseas activ wors clinic
viela develop fusion protein prevent cell
differenti plasma memori cell reduc product pro-
inflammatori mediat exhibit importantli small protein scaffold
fc domain thought caus advers platelet
respons thromboembol complic observ two previou
monoclon antibodi ruplizumab toralizumab
exhibit bind block interact lead autoimmun respons
phase studi rheumatoid arthriti patient proof clinic
activ well-toler treatment-emerg advers event
balanc arm thromboembol event clinic signific coagul
lab abnorm observ addit decreas diseas activ
achiev low diseas activ clinic remiss patient
multipl dose exhibit viela argu dose-depend decreas
autoantibodi level indic effect block
exhibit chang diseas activ rheumatoid factor rf autoantibodi
viela initi phase trial sjgren syndrom sjgren chronic
inflammatori autoimmun diseas affect entir bodi especi
character diminish salivari lacrim gland secret lead dri eye
mouth symptom may includ fatigu joint pain dysfunct
organ estim one four million patient sjgren us
femal mani remain undiagnos cure diseas
symptomat therapi includ eye drop mouth prepar patient may
prescrib immunosuppress medic phase studi begin
primari sjgren patient launch patient sever
diseas like seek therapi assum launch initi gross
price reach peak market share assum po
translat peak adjust sale us assum viela partner
ex-u model low-teen royalti
viela also initi phase trial kidney transplant reject
standard care kidney transplant gener includ combin
pathway blockad belatacept calcineurin inhibitor order prevent
reject howev due toxic calcineurin inhibitor treatment lead
slow deterior kidney function phase studi combin
belatacept hope match efficaci provid favor safeti profil
patient receiv kidney transplant launch model price
peak market share risk-adjust use po translat
peak adjust us sale assum viela partner ex-u model low-
teen royalti
human monoclon antibodi bind plasmacytoid
dendrit cell pdc lead pdc deplet target autoimmun
diseas overproduct type interferon cytokin secret
pdc phase trial test cutan lupu erythematosu cle
system lupu erythematosu sle sjgren system sclerosi polymyos
dermatomyos drug well-toler reduc pdc peripher blood
phase multipl ascend dose portion remain on-going interim data
cle patient cohort expect although primari endpoint
safeti data cohort show secondari endpoint data chang
baselin cle diseas area sever index activ score program remain
upsid model
